PI
OVID icon

Putnam Investments’s Ovid Therapeutics OVID Stock Holding History

Putnam Investments’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-672,763
Closed -$6.64M – 1154
2017
Q4 		$6.64M Buy
+672,763
New +$6.18M 0.01% 458

Other funds holding OVID

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Putnam Investments's OVID Position: Q1 2018 in Review

Putnam Investments sold out of Ovid Therapeutics (OVID) in Q1 2018, closing a stake of 672,763 shares — an estimated $6.64M sold.

Putnam Investments first reported a position in OVID in Q4 2017 and held it in 1 quarter. The position peaked at $6.64M in Q4 2017. 48 funds tracked by Wall St. Rank hold OVID as of Q1 2018.

  • Putnam Investments reported no remaining Ovid Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Putnam Investments sold 672,763 Ovid Therapeutics shares in Q1 2018, an estimated $6.64M.
  • Putnam Investments first reported a position in Ovid Therapeutics in Q4 2017 and held it in 1 quarter.
  • Putnam Investments's Ovid Therapeutics position peaked at $6.64M in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2018.

Based on Putnam Investments's 13F filing for Q1 2018, filed 15 May 2018.